In vitro treatment with an inhibitor of IL-6 (IL-6inh) significantly reduced the cardiomyocyte Fpassive at SLs ranging from 2.0 to 2.4 μm in diabetic AS patients, whereas this effect was only significant at SLs beyond 2.2 μm in the non-diabetic group (Fig. 2F). Here, IL6 is linked to aortic stenosis.